| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platform to Enable Effective Oral Delivery of Therapeutics, Today Announced That It Has Entered Into License and Supply Agreement With Aché Laboratórios Farmacêuitcos s.a (Aché) Granting Exclusive Rights to Market Tlando® in Brazil.
The market for prescription testosterone products in Brazil is substantial and rapidly growing with compound annual growth rate (CAGR) of 34% from 2019 to 2023 and no oral testosterone therapy registered in Brazil.
"We are pleased to partner with Aché, one of the leaders in the Brazilian pharmaceutical market, to further expand the opportunity for TLANDO," said Mahesh Patel, CEO of Lipocine. "Brazil represents an important new growth market, and Aché's established commercial capabilities and proven regulatory expertise make them an ideal partner to bring TLANDO to patients in Brazil."
Under the terms of the agreement, Lipocine has received an upfront payment and is eligible to receive additional payments upon the achievement of certain regulatory milestones and royalties on net sales. Aché assumes full responsibility for the regulatory submission and approval process in Brazil.
Posted In: LPCN
